Abcam, ab277892, Human SMAD7 (MADH7) knockout A549 cell line

Size: 1000000Cells / vial
SMAD7 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SMAD7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MADH7 also known as SMAD7 is an intracellular protein that acts as an inhibitor in the signaling pathway of the TGF-beta (transforming growth factor-beta) family. This protein has a molecular mass of approximately 46 kDa and is widely expressed with a significant presence in tissues involved in immune response and development. SMAD7 directly interacts with receptor-regulated SMADs (R-SMADs) preventing their phosphorylation and consequent nuclear translocation effectively halting further signal transduction.
Biological function summary
SMAD7 functions to regulate the TGF-beta signaling pathway by operating as a negative feedback mediator. It binds to TGF-beta receptors recruiting E3 ubiquitin ligases which promote receptor degradation. SMAD7 is not part of complex large-scale multi-protein assemblies but is essential in modulating the pathway's activity. Its balance controls important processes like cell proliferation differentiation and apoptosis across varied biological contexts.
Pathways
SMAD7 strongly influences the TGF-beta and BMP (bone morphogenetic protein) signaling pathways. SMAD7 blocks TGF-beta signaling by interfering with the activity of R-SMADs such as SMAD2 and SMAD3 and it modulates the BMP pathway by interacting with SMAD1 and SMAD5. Its regulatory roles are tightly integrated within these pathways highlighting its importance in cellular homeostasis and response to extracellular signals.
SMAD7 has links to inflammatory conditions and cancer. Its dysregulation can lead to heightened TGF-beta signaling which may contribute to conditions like fibrosis and can enhance tumor progression by affecting cancer cell dynamics and the tumor microenvironment. In these scenarios abnormal SMAD7 function can associate with proteins such as SMAD3 in fibrosis while in cancer its association with proteins like SMAD4 disrupts normal growth control and cellular response.